This review assessed the overall effect of rapid-cycling (RC) bipolar disorder status on treatment response, and the relative effectiveness of various treatments. Patients with RC bipolar disorder showed a less favorable treatment response than non-RC patients across all treatments. However, the findings should be interpreted with caution due to limited evidence and poor study quality.
Data extraction
Data were extracted into tables under the following headings; study type, treatment, outcome and calculated failure rate. The authors did not state how many reviewers performed the data extraction. The outcome data was extracted as failure rate per month.
Methods of synthesis
How were the studies combined? The studies were combined in a meta-analysis. The main analysis was RC patients versus non-RC patients. The studies that compared the responses of RC patients with non-RC patients were pooled using a random-effects model. Relative risks (RRs) were calculated by dividing the failure rates of RC patients by the failure rates of non-RC patients. Standard errors were also estimated, along with the pooled RR and a 95% confidence interval (CI).
For studies that provided data on both recurrence and non-response outcomes, each outcome was considered separately. A Poisson distribution was used to estimate failure rates and 95% CIs; a random-effects model was used, with weighting based on the inverse variance plus a between-studies variance factor.
The effectiveness of carbamazepine and lithium was compared in a meta-analysis using a random-effects model to calculate a pooled RR and 95% CI. Risk estimates were calculated with an adjustment for estimated drug exposure time.
A 5% significance level was used in each of the analyses
How were differences between studies investigated?
The authors used the chi-squared test to assess heterogeneity between treatment effects.
Results of the review
Sixteen studies (1,856 patients) were included in the review. There were 905 RC patients and 951 non-RC patients.
The average quality rating score was 42.2% plus or minus 21.4%. There were no significant differences among specific drugs.
Nine studies included both RC and non-RC patients. For treatment effects, recurrence (Q=90.2, d.f.=8) and nonimprovement (Q=111.5, d.f.=10) were heterogeneous across studies (both P<0.0001).
At least one recurrence was experienced in 384 out of 505 (76%) RC patients receiving any active treatment, compared with 70 out of 93 (75.3%) RC patients randomised to placebo (9 studies with 15 treatment arms). At least one recurrence was experienced in 287 out of 452 (63.5%) non-RC patients receiving any active treatment, compared with 9 out of 10 (90%) non-RC patients randomised to placebo. The crude rate-estimate of recurrence was 2.31%/month for RC patients and 1.25%/month for non-RC patients.
Risk estimates were also calculated without adjusting for exposure times. This resulted in substantial changes in the magnitude of study-specific risk estimates, with small changes in the relative sizes of risk estimates. Both methods of estimating the risk found a greater risk of treatment failure with RC patients.
Non-improvement was experienced in 264 out of 524 (50.4%) RC patients receiving any active treatment, compared with 309 out of 878 (35.2%) RC patients (11 studies). The crude rate-estimate of recurrence was 1.57%/month for RC patients and 0.48%/month for non-RC patients.
Risk estimates were also calculated without adjusting for exposure times. This resulted in minor differences between treatments in RC cases. Both methods of estimating the risk found a greater risk of treatment failure with RC patients.
The summary statistics indicated a significantly higher rate of treatment failure in RC patients compared with non-RC patients.
